What do systematic reviews say?

Low molecular weight heparin and idraparinux vs usual care

The review found no eligible studies for this question.

• Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs no prophylaxis

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1978 participants
  GRADE not reported

Direct thrombin inhibitors vs low molecular weight heparin

Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 2.06 [1.1, 3.87]
  11 studies · 22065 participants
  Moderate

Subcutaneous unfractionated heparin vs low molecular weight heparin

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).

• Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
  OR 0.73 [0.5, 1.07]
  7 studies · 2272 participants
  Low

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 1.62 [0.57, 4.58]
  3 studies · 5243 participants
  Low